Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4627-30. doi: 10.1016/j.bmcl.2010.06.003. Epub 2010 Jun 8.


Accumulating evidence indicates that the chemokine receptor CCR5 and the chemokine CCL5 may be involved in the proliferation and metastasis of prostate cancer. Consequently, chemokine receptor CCR5 antagonists could potentially act as anti-prostate cancer agents. As the first natural product CCR5 antagonist, anibamine provides a novel chemical structural skeleton compared with other known antagonists identified through high-throughput screening. Our studies demonstrate that anibamine produces significant inhibition of prostate cancer cell proliferation at micromolar to submicromolar concentrations as well as suppressing adhesion and invasion of the highly metastatic M12 prostate cancer cell line. Preliminary in vivo studies indicate that anibamine also inhibits prostate tumor growth in mice. These findings indicate that anibamine may prove to be a novel lead compound for the development of prostate cancer therapeutic agents.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / therapeutic use
  • CCR5 Receptor Antagonists*
  • Cell Line, Tumor
  • High-Throughput Screening Assays
  • Male
  • Mice
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Pyridines / chemistry*
  • Pyridines / therapeutic use
  • Receptors, CCR5 / metabolism


  • Antineoplastic Agents
  • CCR5 Receptor Antagonists
  • Pyridines
  • Receptors, CCR5
  • anibamine